Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance

Basit Öğe Kaydı
dc.contributor.authorDertli, R.
dc.contributor.authorAsil, M.
dc.contributor.authorAtayan, Y.
dc.contributor.authorCosar, U.
dc.contributor.authorYolacan, R.
dc.contributor.authorBiyik, M.
dc.contributor.authorKeskin, M.
dc.date.accessioned2026-04-04T13:33:13Z
dc.date.available2026-04-04T13:33:13Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackgroundHelicobacter pylori (H. pylori) infection is one of the most common infections affecting humanity. As the level of development and socio-economic status of countries decreases, the prevalence of H. pylori infection increases. Although numerous H. pylori eradication regimens have been tested in recent years, the desired level of eradication success has not been achieved. In this study, we aimed to evaluate the effectiveness of alternative treatment protocols.MethodsPatients who presented to our clinic between 2023 and 2024 were included in the study. The patient groups were treated with Rabeprazole (R), Metronidazole (M), Amoxicillin (A), and Bismuth (B) (RMAB), or with Esomeprazole (E), Metronidazole (M), Tetracycline (T), and Bismuth (B) (EMTB) regimens. Patients who were resistant to both RMAB and EMTB treatment protocols received quintuple therapy with RTAMB and ETAMB. All patients were thoroughly informed about their treatment process, management of side effects, and adherence to the therapy.ResultsA total of 611 patients who received H. pylori treatment were included in the study. Of the participants, 60.7% were women, and the mean age was 53.7 +/- 15.2 years. For post-treatment response evaluation, 73.5% (n = 449) of the patients returned to our clinic. The overall H. pylori eradication success rate for the entire patient group was 49.6%. The success rates for patients receiving RMAB and EMTB treatments were 48.2% and 51.3%, respectively. Among the group of patients who were under controlled supervision and had optimal treatment compliance (n = 449), the success rates for the RMAB and EMTB treatments were found to be 66.9% and 68.5%, respectively. A total of 105 patients who were resistant to the RMAB and EMTB treatments were given RTAMB and ETAMB therapy. Of these patients, 96.2% complied with the treatment and underwent a response evaluation. The eradication success rates for patients treated with the RTAMB and ETAMB protocols were 65.6% and 67.6%, respectively.ConclusionIn this study, we demonstrated that bismuth-based quintuple therapy can be used as an alternative to bismuth-based quadruple therapies and other high-risk treatments. However, we also highlighted the critical importance of treatment adherence.
dc.identifier.doi10.1186/s12876-025-04417-6
dc.identifier.issn1471-230X
dc.identifier.issue1
dc.identifier.orcid0000-0003-2076-1934
dc.identifier.pmid41291495
dc.identifier.scopus2-s2.0-105022836039
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12876-025-04417-6
dc.identifier.urihttps://hdl.handle.net/11616/108984
dc.identifier.volume25
dc.identifier.wosWOS:001625189800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectHelicobacter pylori
dc.subjectRabeprazole
dc.subjectEsomeprazole
dc.subjectBismuth
dc.subjectQuadruple therapi
dc.subjectQuintuple therapy
dc.titleBismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu